Erica L. Mayer, MD, MPH, discusses the role of elacestrant in the breast cancer treatment landscape and provides clinical insights on its safety profile.
Kevin Kalinsky, MD, MS, gives an overview of recent data from the EMERALD trial investigating elacestrant in patients with ER+/HER2- advanced breast cancer.
Drs Vidula and Lu review the potential impact of cardiovascular health associated with oral selective estrogen receptor degraders (SERDs) and discuss how the risk of menopausal symptoms differ between oral SERDs and other endocrine therapies.